window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Trixeo recommended for EU approval as asthma maintenance treatment

    AstraZeneca’s Trixeo Aerosphere has been recommended for approval in the [...]

    July 30, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Verdiva Bio starts Phase 1 trial of once-weekly oral amylin drug for obesity

    Verdiva Bio has dosed the first patient in a Phase [...]

    July 30, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development

    Clean Cells acquires Anaquant to expand mass spectrometry capabilities in biopharma quality control

    Clean Cells has acquired French bioanalysis specialist Anaquant in a [...]

    July 30, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development

    Causaly and Sage bring full-text scientific literature to AI drug discovery research

    Causaly has partnered with academic publisher Sage to give its [...]

    July 30, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Research & Development

    Qureight raises $20 million to expand AI imaging platform into new lung and heart diseases

    Qureight has raised $20 million in a Series B financing [...]

    July 30, 2026
  • Clinical & Regulatory,Digital & Data,Medical devices,Research & Development

    Caristo Diagnostics’ CaRi-Heart coronary inflammation technology authorised by US FDA

    Caristo Diagnostics’ CaRi-Heart technology has received US FDA De Novo [...]

    July 30, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    ProMIS reports no ARIA-E in Phase 1b Alzheimer’s trial of PMN310

    ProMIS Neurosciences has reported six-month interim safety and biomarker data [...]

    July 29, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain,Medical devices,Research & Development

    New air filter coating boosts particle capture and doubles filter lifespan

    A new adhesive coating developed by researchers at Pusan National [...]

    July 29, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Research & Development

    Qureight raises $20 million to expand AI imaging platform for clinical trials

    Qureight has raised $20 million in a Series B financing [...]

    July 29, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    HAYA Therapeutics wins FDA Fast Track designation for HTX-001 in heart disease

    HAYA Therapeutics has received FDA Fast Track designation for HTX-001, [...]

    July 29, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug
    Categories: Central Nervous System, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Norstella launches agentic AI platform for biopharma decision-making
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development
  • AI model cuts radiopharmaceutical dose mapping to seconds in prostate cancer study
    Categories: Digital & Data, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top